Clinicopathological significance of miR-101-3p and c-myc mRNA expression in diffused large B-cell lymphoma.

Wenli Cui, Xingyan Zhang, Shutao Zheng, Zhiping Ma, Xuelian Pang, Xinxia Li

Abstract read

In one paragraph

Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wenli CuiDepartment of Pathology, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region, Urumqi 830011, Xinjiang, P.R. China.

Xingyan ZhangDepartment of Pathology, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region, Urumqi 830011, Xinjiang, P.R. China.

Shutao ZhengClinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region, Urumqi 830011, Xinjiang, P.R. China.

Zhiping MaDepartment of Pathology, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region, Urumqi 830011, Xinjiang, P.R. China.

Xuelian PangDepartment of Pathology, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region, Urumqi 830011, Xinjiang, P.R. China.

Xinxia LiDepartment of Pathology, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region, Urumqi 830011, Xinjiang, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MiR-101-3p has been suggested to be implicated in the pathogenesis of lymphoma, however little is known regarding clinicopathological significance of its expression in diffused large B-cell lymphoma (DLBCL). In contrast, although c-myc has been extensively studied in DLBCL, no direct evidence concerning clinicopathological significance has been well established, either. Given this, in our present study, to understand the significance of both miR-101-3p and c-myc expression on mRNA level in DLBCL, real-time quantitative PCR was used to detect the expression of miR-101-3p and c-myc on mRNA level in 100 cases of DLBCL samples. Association between expression of miR-101-3p and c-myc and clinicopathological variables available was statistically analyzed using Cross-Table test. It was shown that only significant association was observed between miR-101-3p expression and histopathological subtype and therapeutic regimen, no significant relationship was found with other clinicopathological variables. As for c-myc expression, only significant association was found with gender, IPI, and activity of LDH in serum; No significant relations were found with other clinicopathological variables. Together, our study presents the direct evidence regarding clinicopathological significance of miR-101-3p and c-myc expression in DLBCL, which warrants further confirmation in different cohorts with larger sample sizes.

Indexed as

c-mycDiffused large B-cell lymphomamiR-101-3pprognosisqPCR

Identifiers

PMID31966543

PMCPMC6966081

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.